InMed Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $6.42M
- P/E (TTM)
- –
- Dividend yield
- –
About InMed Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company engaged in the research and preclinical development of proprietary small molecule drug candidates. The company focuses on developing preferential signaling ligands targeting cannabinoid CB1 and CB2 receptors and other disease-related pathways. Its research pipeline includes INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755 cannabinol cream for epidermolysis bullosa and itch-related conditions. InMed previously operated a commercial operations segment through BayMedica, which constituted its sole revenue-generating unit before being completely wound down. The company aims to advance its pipeline toward clinical trials and pursue licensing or commercial partnerships.
Originally established in British Columbia, Canada, the company operates with a lean organization of six full-time employees and external consultants. InMed maintains its principal mailing address in Vancouver, British Columbia, Canada, and no longer occupies physical executive office space. Its intended regulatory activities and target clinical development span major global jurisdictions, including planned applications in the United States.
Summary of the business section of InMed Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- InMed Pharmaceuticals Inc.
- Founded
- 1981
- Headquarters
- Vancouver, British Columbia, Canada
- Address
- C/O Norton Rose Fulbright Canada Llp, Suite 1800 - 510 West Georgia Street V6B 0M3
- Phone
- (604) 669-7207
- Website
- inmedpharma.com
- Employees
- 6, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- June 30
- Auditor
- CBIZ CPAs P.C., New York, NY
Stock & identifiers
- Ticker
- INM
- Exchange
- Nasdaq
- IPO date
- Nov 16, 2020
- Shares outstanding
- 5M, Sep 2, 2026
- Public float
- $2.97M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Nov 14, 2024; 1-for-20 reverse, Nov 14, 2024; 1-for-25 reverse, Sep 23, 2022; 1-for-25 reverse, Sep 7, 2022; 1-for-33 reverse, Jul 6, 2020
- SEC CIK
- 1728328
- CUSIP
- 457637700
- ISIN
- US4576377000
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric A. Adams | President & CEO, Director | 58,894 |
| Netta Jagpal | Chief Financial Officer | – |
| Shane Aaron Johnson | Sr VP & General Manager | 583,023 |
| Michael Woudenberg | Chief Operating Officer | 530 |
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 1,273 |
| John Steven Bathery | Director | – |
| Andrew Hull | Director | 38,258 |
| Nicole Lemerond | Director | – |
| Neil A. Klompas | Director | – |
| Janet P. Grove | Director | – |
| Bryan T. Baldasare | Director | – |
Employees
Headcount reported in annual reports
“As of September 1, 2026, inclusive of our management team, we had 6 full-time employees, and we also utilize the services of several consultants.”
Corporate history
Events identified from SEC filings